Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050

समान संसाधन

• Biliary effects of liraglutide and sitagliptin, a 12‐week randomized placebo‐controlled trial in type 2 diabetes patients
  द्वारा: Smits, Mark M., और अन्य
  प्रकाशित: (2016)
• Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
  द्वारा: Smits, Mark M., और अन्य
  प्रकाशित: (2016)
• The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
  द्वारा: Sivalingam, Suvanjaa, और अन्य
  प्रकाशित: (2021)
• Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
  द्वारा: Tonneijck, Lennart, और अन्य
  प्रकाशित: (2016)
• Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males
  द्वारा: Smits, Mark M., और अन्य
  प्रकाशित: (2016)